Protocol for a stepped-wedge, cluster randomized controlled trial of the LifeSpan suicide prevention trial in four communities in New South Wales, Australia.


Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
15 Apr 2020
Historique:
received: 03 07 2019
accepted: 17 03 2020
entrez: 16 4 2020
pubmed: 16 4 2020
medline: 15 12 2020
Statut: epublish

Résumé

Despite increasing investment in suicide prevention, Australian suicide rates have increased steadily in the past decade. In response to growing evidence for multicomponent intervention models for reducing suicide, the LifeSpan model has been developed as the first multicomponent, evidence-based, system-wide approach to suicide prevention in Australia. The LifeSpan model consists of nine evidence-based strategies. These include indicated, selective and universal interventions which are delivered simultaneously to community and healthcare systems over a 2-year implementation period. This study will evaluate the effectiveness of the LifeSpan model in reducing suicide attempts and suicide deaths in four geographically defined regions in New South Wales, Australia. We outline the protocol for a stepped-wedge, cluster randomized controlled trial. Following a 6-month transition phase, the trial sites will move to the 2-year active implementation phase in 4-monthly intervals with evaluation extending a minimum of 24 months after establishment of the full active period. Analysis will be undertaken of the change attributable to the invention across the four sites. The primary outcome for the study is the rate of attempted suicide in the regions involved. Rate of suicide deaths within each site is a secondary outcome. If proven effective, the LifeSpan model for suicide prevention could be more widely delivered in Australian communities, providing a valuable new approach to tackle rising suicide rates. LifeSpan has the potential to significantly contribute to the mental health of Australians by improving help-seeking for suicide, facilitating early detection, and improving aftercare to reduce re-attempts. The findings from this research should also contribute to the evidence base for multilevel suicide prevention programs internationally. Australia New Zealand Clinical Trials Register, ID: ACTRN12617000457347. Prospectively registered on 28 March 2017. https://www.anzctr.org.au/TrialSearch.aspx#&&conditionCode=&dateOfRegistrationFrom=&interventionDescription=&interventionCodeOperator=OR&primarySponsorType=&gender=&distance=&postcode=&pageSize=20&ageGroup=&recruitmentCountryOperator=OR Protocol Version: 1.0, 31 May 2019.

Sections du résumé

BACKGROUND BACKGROUND
Despite increasing investment in suicide prevention, Australian suicide rates have increased steadily in the past decade. In response to growing evidence for multicomponent intervention models for reducing suicide, the LifeSpan model has been developed as the first multicomponent, evidence-based, system-wide approach to suicide prevention in Australia. The LifeSpan model consists of nine evidence-based strategies. These include indicated, selective and universal interventions which are delivered simultaneously to community and healthcare systems over a 2-year implementation period. This study will evaluate the effectiveness of the LifeSpan model in reducing suicide attempts and suicide deaths in four geographically defined regions in New South Wales, Australia.
METHODS METHODS
We outline the protocol for a stepped-wedge, cluster randomized controlled trial. Following a 6-month transition phase, the trial sites will move to the 2-year active implementation phase in 4-monthly intervals with evaluation extending a minimum of 24 months after establishment of the full active period. Analysis will be undertaken of the change attributable to the invention across the four sites. The primary outcome for the study is the rate of attempted suicide in the regions involved. Rate of suicide deaths within each site is a secondary outcome.
DISCUSSION CONCLUSIONS
If proven effective, the LifeSpan model for suicide prevention could be more widely delivered in Australian communities, providing a valuable new approach to tackle rising suicide rates. LifeSpan has the potential to significantly contribute to the mental health of Australians by improving help-seeking for suicide, facilitating early detection, and improving aftercare to reduce re-attempts. The findings from this research should also contribute to the evidence base for multilevel suicide prevention programs internationally.
TRIAL REGISTRATION BACKGROUND
Australia New Zealand Clinical Trials Register, ID: ACTRN12617000457347. Prospectively registered on 28 March 2017. https://www.anzctr.org.au/TrialSearch.aspx#&&conditionCode=&dateOfRegistrationFrom=&interventionDescription=&interventionCodeOperator=OR&primarySponsorType=&gender=&distance=&postcode=&pageSize=20&ageGroup=&recruitmentCountryOperator=OR Protocol Version: 1.0, 31 May 2019.

Identifiants

pubmed: 32293516
doi: 10.1186/s13063-020-04262-w
pii: 10.1186/s13063-020-04262-w
pmc: PMC7161184
doi:

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

332

Références

Suicide Life Threat Behav. 2017 Dec;47(6):672-687
pubmed: 28044354
Aust N Z J Psychiatry. 2016 Feb;50(2):115-8
pubmed: 26698822
JAMA. 2005 May 25;293(20):2487-95
pubmed: 15914749
Lancet Psychiatry. 2016 Jul;3(7):646-59
pubmed: 27289303
BMJ. 2003 Dec 13;327(7428):1376
pubmed: 14670880
BMC Psychiatry. 2019 Jan 7;19(1):6
pubmed: 30616582
Suicide Life Threat Behav. 2012 Dec;42(6):640-53
pubmed: 22971238
BMC Psychiatry. 2017 Oct 6;17(1):339
pubmed: 28985736
World J Biol Psychiatry. 2008;9(1):51-8
pubmed: 17853299
Depress Anxiety. 2011 Nov;28(11):963-72
pubmed: 21948348
Depress Anxiety. 2016 Jun;33(6):520-30
pubmed: 26854478

Auteurs

Fiona Shand (F)

Black Dog Institute, University of New South Wales, Sydney, NSW, Australia. fionas@unsw.edu.au.

Michelle Torok (M)

Black Dog Institute, University of New South Wales, Sydney, NSW, Australia.

Nicole Cockayne (N)

Black Dog Institute, University of New South Wales, Sydney, NSW, Australia.

Philip J Batterham (PJ)

Centre for Mental Health Research, Australian National University, Canberra, NSW, Australia.

Alison L Calear (AL)

Centre for Mental Health Research, Australian National University, Canberra, NSW, Australia.

Andrew Mackinnon (A)

Black Dog Institute, University of New South Wales, Sydney, NSW, Australia.

Dean Martin (D)

Black Dog Institute, University of New South Wales, Sydney, NSW, Australia.

Isabel Zbukvic (I)

Black Dog Institute, University of New South Wales, Sydney, NSW, Australia.

Katherine Mok (K)

Black Dog Institute, University of New South Wales, Sydney, NSW, Australia.

Nicola Chen (N)

Black Dog Institute, University of New South Wales, Sydney, NSW, Australia.

Lauren McGillivray (L)

Black Dog Institute, University of New South Wales, Sydney, NSW, Australia.

Matthew Phillips (M)

Black Dog Institute, University of New South Wales, Sydney, NSW, Australia.

Henry Cutler (H)

Macquarie University Centre for Health Economics, Macquarie University, Sydney, NSW, Australia.

Brian Draper (B)

School of Psychiatry, University of New South Wales, Sydney, NSW, Australia.

Grant Sara (G)

System Information and Analytics Branch, NSW Ministry of Health, Sydney, NSW, Australia.
Northern Clinical School, Sydney Medical School, University of Sydney, Sydney, NSW, Australia.

Helen Christensen (H)

Black Dog Institute, University of New South Wales, Sydney, NSW, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH